Factors prognostic of PR-OS on multivariate analysis
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| Age at auto-HCT, decades | 1.25 | 1.06-1.48 | .009 |
| Timing of relapse post–auto-HCT, mo | |||
| ≤3 | 1 | ||
| 3-6 | 0.56 | 0.36-0.84 | .006 |
| 6-12 | 0.37 | 0.23-0.61 | <.0001 |
| >12 | 0.21 | 0.13-0.34 | <.0001 |
| Disease status at auto-HCT | |||
| Partial response | 1 | .07 | |
| CR | 0.75 | 0.54-1.03 |
| . | HR . | 95% CI . | P . |
|---|---|---|---|
| Age at auto-HCT, decades | 1.25 | 1.06-1.48 | .009 |
| Timing of relapse post–auto-HCT, mo | |||
| ≤3 | 1 | ||
| 3-6 | 0.56 | 0.36-0.84 | .006 |
| 6-12 | 0.37 | 0.23-0.61 | <.0001 |
| >12 | 0.21 | 0.13-0.34 | <.0001 |
| Disease status at auto-HCT | |||
| Partial response | 1 | .07 | |
| CR | 0.75 | 0.54-1.03 |
Variables included in multivariate analysis: era of auto-HCT, age at auto-HCT, Eastern Cooperative Oncology Group performance status at auto-HCT, disease status at auto-HCT, time from auto-HCT to relapse, allogeneic HCT, and clinical trial participation.
HR, hazard ratio.